Praga C., Beretta G., Vigo PL, et al: Adriamycin cardiotoxicity: A survey of 1,273 patients. Cancer Treat Rep63:827-834, 1979
2.
Von Hoff DD, Layard MW, Basa P., et al: Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med91:710-717, 1979
3.
Von Hoff DD, Rozencweig M., Layard M., et al: Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases. Am J Med62:200-208, 1977
4.
Saltiel E., McGuire W.: Doxorubicin (Adriamycin) cardiomyopathy. West J Med139:332-341, 1983
5.
Buzdar AU, Marcus C., Smith TL, et al: Early and delayed clinical cardiotoxicity of doxorubicin. Cancer55: 2761-2765, 1985
6.
Billingham ME , Mason GW, Bristow MR, et al: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep62:865-872, 1978
7.
Ferrans VJ: Overview of cardiac pathology in relation to anthracycline cardiotoxicity . Cancer Treat Rep62:955-961, 1978
8.
Bristow MR, Mason JW, Billingham ME, et al: Dose-effect and structure function relationships in doxorubicin cardiomyopathy. Am Heart J102:709-718, 1981
9.
Bachur NR, Gordon SL, Gee MV: A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer38:1745-1752, 1977
10.
Myers CE, Chabner BA: Anthracyclines, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 356-381
11.
Demant Ejf, Nørskov-Lauritsen N.: Binding of transferrin-iron by adriamycin at acidic Ph. FEBS Lett196:321-324,1986
12.
Thomas CE, Aust SE: Release of iron from ferritin by cardiotoxic anthracycline antibiotics . Arch Biochem Biophys248:684-695, 1986
13.
Myers CE, Gianni L., Zweier J., et al: The role of iron in adriamycin biochemistry. Fed Proc45:2792-2797, 1986 14. Myers CE, Liss RH, Ifrim J., et al: The role of lipid peroxidation on cardiac toxicity and tumor response. Science197:165-167,1977
14.
Doroshow JH : Effect of anthracycline antibiotics on oxygen radical formation in the rat heart. Cancer Res43:460-472, 1983
15.
Singal PK, Pierce GN: Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation by depresses cardiac function. Am J Physiol250:H419-H425, 1986
16.
Griffin-Green EA, Zaleska MM, Ericinska M.: Adriamycin-induced lipid peroxidation in mitochondria and microsomes. Biochem Pharmacol37:3071-3077,1988
17.
Doroshow JH, Locker GH, Myers CE: Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest65:128-135,1980
18.
Goodman J., Hochstein P.: Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun77:797-803, 1977
19.
Billingham ME, Bristow MR, Glatstein E., et al: Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol1:17-23,1977
20.
Minow RA, Benjamin RS, Gottlieb JA: Adriamycin (NSC-123127) cardiomyopathy: An overview with determination of risk factors. Cancer Treat Rep6:195-201, 1975
21.
Piver MS, Marchetti DL, Parthasarathy KL, et al: Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiography. Cancer56:76-80, 1985
22.
Dukart G., Posner L., Henry D., et al: Comparative cardiotoxicity of motoxantrone vs. doxorubicin. Proc Am Soc Clin Oncol5:48, 1986 (abstr)
23.
Kharasch ED , Novak RF: Inhibition of adriamycin-stimulated microsomal lipid peroxidation by mitoxantrone and amentantrone. Biochem Biophys Res Commun108: 1346-1352, 1982
24.
Butler J., Hoey BM: Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?Br J Cancer55:53-59, 1987 (suppl)
25.
Clark GM, Tokaz LK, von Hoff DD, et al: Cardiotoxicity in patients treated with mitoxantrone on Southwest Oncology Group phase II protocols. Cancer Treat Symp3:25-30,1984
26.
Aapro MS, Alberts DS, Woolfenden JM, et al: Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone. Invest New Drugs1:341-347, 1983
27.
Unverferth DV, Underferth BJ, Balcerzak SP, et al: Cardiac evaluation of mitoxantrone . Cancer Treat Rep67:343-350, 1983
28.
Prai GR, Reed NS, Ruddell NS: A case of mitoxantrone-associated cardiomyopathy without prior anthracycline therapy. Br J Radiol60:1125-1126, 1987
29.
Crossley RJ : Clinical safety and tolerance of mitoxantrone . Semin Oncol11:54-58, 1984 (suppl)
30.
Skenkenberg TD, Von Hoff DD: Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med105:67-81, 1986
31.
Gottdiener JS, Appelbaum FR, Ferrans FJ, et al: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med141:758-763, 1981
32.
Buckner CD, Rudolph RJ, Fefer A., et al: High dose cyclophosphamide therapy for malignant disease. Cancer29:357-365, 1972
33.
Colvin M., Chabner BA: Alkylating agents, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 276-313
34.
Applebaum FR , Strauchen JA, Graw RG: Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet1:58-62, 1976
35.
Cazin B., Gorin NC, Laporte JP, et al: Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer57:2061-2069,1986
36.
Weiss RB, Grillo-Lopez AJ, Marsoni S., et al: Amsacrine-associated cardiotoxicity: An analysis of 82 cases . J Clin Oncol4:918-928, 1986
37.
Lowe MC: In vitro evaluation of the cardiotoxic potential of AMSA. Cancer Treat Rep66:1571-1573, 1982
38.
Venveij J., van der Burg ME, Pinedo HM: Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug . Radiother Oncol8:33-41, 1987
39.
Buzdar AU, Legha SW, Tashima CK, et al: Adriamycin and mitomycin C: Possible synergistic cardiotoxicity . Cancer Treat Rep62:1005-1008, 1978
40.
Bristow MR, Lopez MB, Jason JW, et al: Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer50:32-41, 1982
41.
Schwartz RG , McKenzie WB, Alexander J., et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med82:1109-1118, 1987
42.
Vorobiof DA , Iturralde M., Falkson G.: Amsacrine cardiotoxicity: Assessment of ventricular function by radionuclide angiography. Cancer Treat Rep67:1115-1117, 1983 44. Legha SS, Benjamin RS, Mackay B., et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann Intern Med66:13-139, 1982
43.
Valdivieso M., Burgess MA, Ewer MS, et al: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study. J Clin Oncol2:207-214, 1984
44.
Torti FM, Bristow MR, Howes AE, et at: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med99:745-749, 1983
45.
Saltiel E., McGuire W.: Doxorubicin (Adriamycin) cardiomyopathy: A critical review. West J Med139:332-341, 1983
46.
Myers CE, Gianni L., Simone CB, et al: Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry21:1707-1712, 1982
47.
Speyer JL, Green MD, Kramer E., et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer . N Engl J Med319:745-752, 1988
48.
Saini J., Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity . Ann Intern Med106:814-816, 1987
49.
Gross NJ: Pulmonary effects of radiation therapy. Ann Intern Med86:81-92,1977
50.
O'Driscoll BR, Hasleton PS, Taylor PM, et al: Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood . N Engl J Med323:378-382,1990
51.
Weiss T., Poster D., Penta J.: The nitrosoureas and pulmonary toxicity. Cancer Treat Rev8:111-125,1981
52.
Cordonnier C. , Vernant JP, Mital P., et al: Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer51:1814-1818, 1983
53.
Heard BE, Cooke RA: Busulfan lung. Thorax23:187-193, 1968
54.
Burns WA, McFarland W., Matthews MJ: Busulfan-induced pulmonary disease. Report of a case and review of the literature . Am Rev Respir Dis101:408-413, 1970
55.
Mark GJ, Lehimgar-Zadeh A., Ragsdale BD: Cyclophosphamide pneumonitis. Thorax33:89-93, 1978
56.
Patel AR, Shah. PC, Rhee HL, et al: Cyclophosphamide therapy and interstitial pulmonary fibrosis . Cancer38:1542-1549, 1976
Venveij J., van Zanten T., Souren T., et al: Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer60:756-761, 1987
62.
Chang AY, Kuebler JP, Pandya KJ, et al: Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids. Cancer57:2285-2290, 1986
63.
Gunstream SR , Seidenfeld JJ, Sobonya RE, et al: Mitomycin-associated lung disease . Cancer Treat Rep67: 301-304, 1983
64.
St Clair EW , Rice JR, Snyderman R.: Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med145:2035-2038, 1985
65.
Phillips TJ , Jones DH, Baker H.: Pulmonary complications following methotrexate therapy. J Am Acad Dermatol16:373-375; 1987
66.
Haupt HM, Hutchins GM, Moore GW: Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. Am J Med70:256-261, 1981
67.
Konits PH, Aisner J., Sutherland JC, et al: Possible pulmonary toxicity secondary to vinblastine. Cancer50:2771-2774, 1982
68.
Jones SE, Moore M., Blank N., et al: Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer29:498-500, 1972
69.
Freeman BA, Crapo JD: Biology of disease: Free radicals and tissue injury. Lab Invest47:412-426, 1982
70.
Lewis RA, Austen KF: The biologically active leukotrienes: Biosynthesis, metabolism, receptors, functions and pharmacology. J Clin Invest73:889-897, 1984
71.
Cooper JA, White DA, Matthay RA: Drug-induced pulmonary disease: Part 1: Cytotoxic drugs. Am Rev Respir Dis133:321-340, 1986
72.
L'age-Stehr J., Diamanstein T.: Induction of autoreactive T lymphocytes and their suppressor cells by cyclophosphamide. Nature271:663-665, 1978
73.
Absher M., Hildebran J., Trombley L., et al: Characteristics of cultured lung fibroblasts from bleomycin-treated rats. Comparison with in vitro exposed normal fibroblasts. Am Rev Respir Dis129:125-129,1984
74.
Holoye PY, Luna MA, MacKay B., et al: Bleomycin hypersensitivity pneumonitis. Ann Intern Med88:47-49, 1978
75.
Blum RH, Carter SK, Agre K.: A clinical review of bleomycin—A new antineoplastic agent. Cancer31:903-914, 1973
76.
Einhorn L., Krause M, Hornback, et al: Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer. Cancer37:2414-2416, 1976
77.
Samuels ML, Johnson De, Holoye PY, et al: Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA235:1117-1120, 1976
78.
Goldiner PL , Carlon GC, Cvitkovic E., et al: Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J1:1664-1667, 1978
79.
Parvinen LM , Kilkku P., Makinen E., et al: Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol22:417-421, 1983
80.
Bauer KA, Skarin AT, Balikian JP, et al: Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med74:557-563, 1983
81.
Perry DJ, Weiss RB, Taylor HG: Enhanced bleomycin toxicity during acute renal failure. Cancer Treat Rep66:592-593,1982
82.
Bechard DE, Fairman RP, DeBlois GG, et al: Fatal pulmonary fibrosis from low-dose bleomycin therapy. South Med J80:646-649, 1987
83.
Iacovino JR , Leitner J., Abbas AK, et al: Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response. JAMA235:1253-1255,1976
84.
De Lena M., Guzzon A., Monfardini S., et al: Clinical, radiologic, and histopathologic studies on pulmonary toxicity induced by treatment with bleomycin (NSC-125066). Cancer Chemother Rep56:343-356, 1972
85.
Ginsberg SJ , Comis RL: The pulmonary toxicity of antineoplastic agents. Semin Oncol9:34-51, 1982
86.
Chabner BA: Bleomycin, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 341-355
Pascual RS, Mosher MB, Sikand RS, et al: Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis108:211-217, 1973
89.
Van Barneveld PW, Van der Mark TW, Sleijfer DT, et al: Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis130:1078-1081, 1984
90.
Conley NS, Yarbro JW, Ferrari HA, et al: Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages. Mol Pharmacol30:48-52, 1986
91.
Ishizuka M., Takayama H., Takeuchi T., et al: Activity and toxicity of bleomycin. J Antibiot (Tokyo) 20:15-24,1967
92.
Ohnuma T., Holland JF, Masuda H., et al: Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance. Cancer33:1230-1238, 1974
93.
Filderman AE , Genovese LA, Lazo JS: Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol37:1111-1116, 1988
94.
Breul SD, Bradley KH, Hance AJ, et al: Control of collagen production by human diploid lung fibroblasts . J Biol Chem255:5250-5260,1980
95.
Lee W., Moore RP, Wampler GL: Interstitial pulmonary fibrosis as a complication of prolonged methyl-CCNU therapy. Cancer Treat Rep62:1355-1358, 1978
96.
Koss LG, Melamet MR, Mayer K.The effect of busulfan on human epithelia. Am J Clin Pathol44:385-397, 1965
97.
Codling BW, Chakera Tmh: Pulmonary fibrosis following therapy with melphalan for multiple myeloma . J Clin Pathol25:668-673, 1972
98.
Maxwell I. : Reversible pulmonary edema following cyclophosphamide treatment. JAMA229:137-138, 1974
99.
Abdel Karim FW, Ayash RE, Allam C., et al: Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. Oncology40:174-176, 1983
100.
Carson CW, Cannon CW, Egger JM, et al: Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate. Semin Arthritis Rheum16:186-195,1987
101.
Sostman HD , Matthay RA, Putman C., et al: Methotrexate-induced pneumonitis. Medicine55:371-388, 1976 104. From E.: Methotrexate pneumonitis in a psoriatic. Br J Derm93:107-110, 1975
Allegra CJ: Antifolates, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 110-153
104.
Klein DS, Wilds PR: Pulmonary toxicity of antineoplastic agents: Anaesthetic and postoperative implications. Can Anaesth Soc J30:399-405, 1983
105.
Sikic BI, Collins JM, Mimmnaugh EG, et al: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep62:2011-2017,1978
106.
Crystal RG , Gadek JE, Ferrans VJ, et al: Interstitial lung disease: Current concepts of pathogenesis, staging and therapy. Am J Med70:542-568,1981
107.
Weber BL, Tanyer G., Poplack DG, et al: Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr5:207-212, 1987
108.
Paulus HE: FDA arthritis advisory committee meeting: Methotrexate; Guidelines for the clinical evaluation of antiinflammatory drugs; DMSO in scleroderma . Arthritis Rheum29:1289-1290,1986
Dahl MG, Gregory MM, Scheuer PJ: Liver damage due to methotrexate in patients with psoriasis. Br Med J1:625-630, 1971
111.
Tolman KG, Clegg DO, Lee RG, et al: Methotrexate and the liver. J Rheumatol12:29-34, 1985 (suppl)
112.
Weinstein GD, Cox JW, Suringa DW, et al: Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis. Arch Derm102:613-618, 1970
113.
Reynolds FS , Lee WM: Hepatotoxicity after long-term methotrexate therapy. South Med J79:536-539,1988
114.
Einhorn M. , Davidsohn I.: Hepatotoxicity of 6-mercaptopurine . JAMA188:802-806, 1964
115.
Key NS, Emerson PM, Allan NC, et al: Oesophageal varices associated with busulphan-thioguanine combination therapy for chronic myeloid leukemia. Lancet2:1050-1052, 1987
116.
Clark PA, Hsia YE, Huntsman RG: Toxic complications of treatment with 6-mercaptopurine: Two cases with hepatic necrosis and intestinal ulceration. Br Med J1:393-395, 1960
117.
Perry MC: Hepatotoxicity of chemotherapeutic agents. Semin Oncol9:65-74, 1982
118.
Monto RW, Talley RW, Caldwell MJ, et al: Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC-24559) therapy. Cancer Res29:697-704, 1969
119.
McClay E., Lusch CJ, Mastrangelo MJ: Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep71:219-220,1987
120.
Greenstone MA, Dowd PM, Mikhailidis DP, et al: Hepatic vascular lesions associated with dacarbazine treatment. Br Med J282:1744-1745, 1982
121.
Ceci G., Bella M., Melissari M., et al: Fatal hepatic vascular toxicity of DTIC: Is it really a rare event?Cancer61:1988-1991,1988
122.
DeVita VT, Carbone PP, Owens AH, et al: Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962 . Cancer Res25:1876-1881, 1965
123.
Bacon AM, Rosenberg SA: Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus . Ann Intern Med97:62-63, 1982
124.
D'Angio GJ : Hepatotoxicity with actinomycin D. Lancet2:104, 1987 (lettr)
125.
Slavin RE, Dias MA, Saral R.: Cytosine arabinoside-induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer42:1747-1759, 1978
126.
Pratt CB, Johnson WW: Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer28:361-364, 1971
Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: Observation of disabling neurotoxicity. J Clin Oncol3:1373-1378, 1985
129.
Hadley D., Herr HW: Peripheral neuropathy associated with cis-dichlorodiammine platinum (II) treatment . Cancer44:2026-2028, 1979
130.
Trugman J. , Hogenkamp HP, Roelofs R., et al: Cisplatin neurotoxicity: Failure to demonstrate vitamin B12 inactivation. Cancer Treat Rep69:453-455, 1985
131.
VonHoff DD , Schilsky R., Reichert CM, et al: Toxic effects of Cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep63:1527-1531, 1979
132.
Piel JJ, Meyer D., Perlia CP, et al: Effects of Cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep58:871-875, 1974
133.
Fleming S., Peppard S., Ratanatharathorn V., et al: Ototoxicity from cis-platinum in patients with stages III and IV previously untreated squamous cell cancer of the head and neck. Am J Clin Oncol8:302-306, 1985
134.
Wilding G. , Caruso R., Lawrence TS, et al: Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol3:1683-1689, 1985
135.
Aass N., Kaasa S., Lund E., et al: Long-term somatic side-effects and morbidity in testicular cancer patients. Br J Cancer61:151-155, 1990
136.
Cowan JD, Kies MS, Roth JL, et al: Nerve conduction studies in patients treated with cis-diamminedichloroplatinum (II): A preliminary report. Cancer Treat Rep64:1119-1122,1980
137.
Schaefer SD , Post JD, Close LG, et al: Ototoxicity of low- and moderate-dose cisplatin. Cancer56:1934-1939, 1985
138.
Reed E., Kohn KW: Platinum analogues, in Chabner BA , Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 456-490
139.
Granowetter L., Rosenstock JG, Packer RJ: Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol1:293-297, 1983
140.
Schweitzer VG, Rarey KE, Dolan DF, et al: Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg94:458-470, 1986
141.
Whitelaw DM , Cowan DH, Cassidy FR, et al: Clinical experience with vincristine . Cancer Chemother Rep30:13-20, 1963
142.
Desai ZR, Van den Berg HW, Bridges JM, et al: Can severe vincristine neurotoxicity be prevented?Cancer Chemother Pharmacol8:211-214, 1982
143.
Bender RA, Hamel E., Hande KR: Plant alkaloids, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 253-275
144.
Sandler SG , Tobin W., Henderson ES: Vincristine-induced neuropathy: A clinical study of fifty leukemic patients. Neurology19:367-374, 1969
145.
Casey EB, Jellife AM, LeQuesne PM, et al: Vincristine neuropathy: Clinical and electrophysiological observations . Brain96:69-86, 1973
146.
Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med291:71-81, 127-133, 1974
147.
Holland JF , Scharlav C., Gailani S., et al: Vincristine treatment of advanced cancer: A cooperative study of 392 cases. Cancer Res33:1258-1264,1973
148.
Rosenthal S., Kaufman S.: Vincristine neurotoxicity. Ann Intern Med80:733-737, 1974
149.
Cassady JR , Tonnesen GL, Wolfe LC, et al: Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves. Cancer Treat Rep64:963-965, 1980
150.
Taylor SG, Desai SA, DeWys WD: Phase II trial of a combination of cyclophosphamide, vincristine, and methotrexate in advanced colorectal cancer. Cancer Treat Rep62:1203-1205,1978
151.
Griffiths JD, Stark RJ, Ding JC, et al: Vincristine neurotoxicity enhanced in combination chemotherapy including both teniposide and vincristine. Cancer Treat Rep70:519-521, 1986
152.
Bradley WG , Lassman LP, Pearce GW, et al: The neuropathy of vincristine in man: Clinical, electrophysiological, and pathological studies . J Neurol Sci10:107-131, 1970
153.
Finley RS, Fortner CL, Grove WR: Cisplatin nephrotoxicity: A summary of preventative interventions . Drug Intell Clin Pharm19:362-367, 1985
154.
Gonzales-Vitale JC, Hayes DM, Cvitkovic E., et al: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer39:1362-1371, 1977
155.
Groth S., Nielsen H., Sørensen JB, et al: Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol17:191-196,1986
156.
Dentino M. , Luft FC, Yum MN, et al: Long-term effect of cis-diammine-dichloroplatinum (CDDP) on renal function and structure in man. Cancer41:1224-1281, 1978
157.
Blachley JD , Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med95:628-632, 1981
158.
Hutchison FN, Perez EA, Gandara DR, et al: Renal salt wasting in patients treated with cisplatin. Ann Intern Med108:21-25, 1988
159.
Jones BR, Bhalla RB, Mladek J., et al: Comparison of methods of evaluating nephrotoxicity of cis-platinum . Clin Pharmacol Ther27:557-562, 1980
160.
Meijer S., Sleisfer D., Mulder NH, et al: Some effects of combination chemotherapy with cis-platinum on renal function in patients with non seminomatous testicular carcinoma. Cancer51:2035-2040, 1983
161.
Bodenner DL , Dedon PC, Keng PC, et al: Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition. Cancer Res46: 2745-2750,1986
162.
Dedon PC, Borch RJ: Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol36:1955-1964,1987
163.
Nanji AA, Stewart DJ, Mikhael NZ: Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity . Cancer Chemother Pharmacol17:274-276, 1986 167. Kelsen DP, Alcock N., Young CW: Cisplatin nephrotoxicity: Correlation with plasma platinum concentration. Am J Clin Oncol8:77-80, 1985
164.
Ozols RF, Corden BJ, Jacob J., et al: High-dose cisplatin in hypertonic saline. Ann Intern Med100:19-24, 1984
165.
Salem P., Khatyl M., Jabboury K., et al: Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer53:837-840,1984
166.
Schilsky RL : Renal and metabolic toxicities of cancer chemotherapy . Semin Oncol9:75-83, 1982
167.
Pera MF, Harder HD: Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum (II) in rats. Cancer Res39:1269-1278,1979
168.
Glover DJ, Glick JH, Weiler C., et al: WR-2721 and high dose cisplatin: An active combination in metastatic melanoma. J Clin Oncol5:574-578,1987
169.
Glover D., Glick J., Weiler C., et al: Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Physiol12:1509-1512,1986
170.
Pitman SW, Parker LM, Tatersall Mhn, et al: Clinical trial of high dose methotrexate (NSC740) with citrovorum factor (NSC3590): Toxicologic and therapeutic observations. Cancer Chemother Rep6:43-49, 1975
171.
Condit PT, Chanes RE, Joel W.: Renal toxicity of methotrexate. Cancer23:126-131, 1969
Jacobs SA, Stoller RG, Chabner BA, et al: 7-Hydroxy methotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J Clin Invest57:534-538, 1976
174.
Taylor SG, McGuire WP, Hauck WW, et al: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol2:1006-1011, 1984
175.
Ettinger DS , Stanley KE, Nystrom JS: Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group study. Cancer Treat Rep64:1017-1021, 1980
176.
Schacht RG , Feiner HD, Gallo GR, et al: Nephrotoxicity of nitrosoureas. Cancer48:1328-1334, 1981
177.
Harmon WE, Cohen HJ, Schneeberger EE, et al: Chronic renal failure in children treated with methyl CCNU. N Engl J Med300:1200-1203,1979
178.
Silver Hkb , Morton DL: CCNU nephrotoxicity following sustained remission in oat cell carcinoma. Cancer Treat Rep63:226-227, 1979
179.
Micetich K. , Jensen-Akula M., Mandard J., et al: Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy. Am J Med71:967-972,1981
180.
Moertel CG , Reitemeier RJ, Schutt AJ, et al: Phase II study of streptozotocin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep55:303-307, 1981
181.
Fennell JS , Falls WF Jr: Streptozotocin nephrotoxicity: Studies on the defect in renal tubular acidification. Clin Nephrol15:97-101, 1981
182.
DeFronzo RA , Braine HG, Colvin M., et at: Water intoxication in man after cyclophosphamide therapy. Ann Intern Med78:861-869,1973
183.
DeFronzo RA , Colvin OM, Braine H., et al: Cyclophosphamide and the kidney. Cancer33:483-491, 1974
Buzdar AV, Legha SS, Tashima CK, et al: Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast carcinoma. Cancer Treat Rep63:115-119,1979
192.
Colvin M., Chabner BA: Alkylating agents, in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice. Philadelphia, PA, Lippincott, 1990, pp 276-313
193.
Andriole GL , Sandlund JT, Miser JS, et al: The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy . J Clin Oncol5:799-803, 1987
194.
Shrom SH, Donaldson MH, Ducket JW, et al: Formalin treatment for intractable hemorrhagic cystitis. Cancer38:1785-1789, 1976
195.
Ehrlich RM , Freedman A., Goldsobel AB, et al: The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. J Urol131:960-962, 1984
196.
Primack A. : Amelioration of cyclophosphamide-induced cystitis . J Natl Cancer Inst47:223-227, 1971
197.
Jackson H. , Fox BW, Craig AW: Antifertility substances and their assessment in the male rodent. J Reprod Fertil2:447-465, 1961
198.
Jackson H. : The effects of alkylating agents on fertility . Br Med Bull20:107-114, 1964
199.
Lu CC, Meistrich ML: Cytotoxic effects of chemotherapeutic drugs on mouse testis cells . Cancer Res39:3575-3582,1979
200.
Meistrich ML, Finch M., da Cunha MF, et al: Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res42:122-131, 1982
201.
Fairley KF , Barrie JU, Johnson W.: Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet1:568-569, 1972
202.
Richter P. , Calamera JC, Morgenfeld MC, et al: Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer25:1026-1030, 1970
203.
Mecklenberg RS, Sherins RJ: Gonadotropin response to luteinizing hormone releasing hormone in men with germinal aplasia. J Clin Endocrinol Metab38:1005-1009, 1974
204.
Whitehead E., Shalet SM, Blackledge G., et al: The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer49:418-422, 1982
205.
Sherins RJ , DeVita VT: Effects of drug treatment for lymphoma on male reproductive capacity. Ann Intern Med79:216-220,1976
206.
da Cunha MF , Meistrich ML, Fuller ML, et al: Recovery of spermatogenesis after treatment for Hodgkin's disease: Limiting dose of MOPP chemotherapy. J Clin Oncol2:571-577, 1984
207.
Miller JJ, Williams GF, Leissring JC: Multiple late complications of therapy with cyclophosphamide including ovarian destruction. Am J Med50:530-535, 1971
208.
Schilsky RL, Erlichman C.: Infertility and carcinogenesis: Late complications of chemotherapy , in Chabner BA, Collins JM (eds): Cancer Chemotherapy Principles and Practice . Philadelphia, PA, Lippincott , 1990, pp 32-58
209.
Siris EJ, Leventhal BG, Vaitukaitis JL: Effects of childhood leukemia and chemotherapy on pubert and reproductive function in girls. N Engl J Med294:1143-1146, 1976
210.
Henne T., Schmähl D.: Occurrence of second primary malignancies in man—a second look . Cancer Treat Rev12:77-94, 1985
211.
Kushner BH , Zauber A., Tan Ctc: Second malignancies after childhood Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience. Cancer62:1364-1370,1988
212.
Fraser MC, Tucker MA: Late effects of cancer therapy: Chemotherapy-related malignancies . Oncol Nurs Forum15:67-77, 1988
213.
Pedersen-Bjergaard J., Larsen SO: Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med307:965-971, 1982
214.
Bradley EC , Schechter GP, Matthews MJ: Erythroleukemia and other hematologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer49:221-223, 1982
215.
Pedersen-Bjergaard J., Ersbøll J., Sørensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Ann Intern Med103:195-200, 1985
216.
Pui CH, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med321:136-142, 1989
217.
Greene MH, Boice JD, Greer BE, et al: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med307:1416-1421, 1982
218.
Boice JD, Greene MH, Killen JY, et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med309:1079-1084,1983
219.
Reimer RR, Hoover R., Fraumeni JF, et al: Acute leukemia after alkylating-agent therapy of ovarian cancer . N Engl J Med177-181, 1977
220.
Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med318:76-81, 1988
221.
Pedersen-Bjergaard J., Ersbøll J., Hansen VL, et al: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med318:1028-1032, 1988
222.
Seidenfeld AM, Smyth HA, Ogryzlo MA, et al: Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol3:295-304, 1976
223.
Baker GL, Kahl LE, Zee BC, et al: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide . Am J Med83:1-9,1987
224.
Helm F., Helm TN: Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema . Cutis39:219-223, 1987
225.
Boivin JF: Second cancers and other late side effects of cancer treatment: A review. Cancer65:770-775, 1990
226.
Greene MH, Harris EL, Gershenson DM, et al: Melphalan may be a more potent leukemogen than cyclophosphamide . Ann Intern Med105:360-367, 1986
